Progressive multifocal leukoencephalopathy

Shaun Zhai; Bruce James Brew

doi:10.1016/B978-0-444-63849-6.00010-4

Progressive multifocal leukoencephalopathy

Handb Clin Neurol. 2018:152:123-137. doi: 10.1016/B978-0-444-63849-6.00010-4.

Authors

Shaun Zhai¹, Bruce James Brew²

Affiliations

¹ Department of Neurology, St. Vincent's Hospital, Sydney, NSW, Australia.
² Department of Neurology, St. Vincent's Hospital, Sydney, NSW, Australia; Department of HIV Medicine and Peter Duncan Neurosciences Unit, St. Vincent's Centre for Applied Medical Research, St. Vincent's Hospital, Sydney, NSW, Australia. Electronic address: B.Brew@UNSW.edu.au.

PMID: 29604971
DOI: 10.1016/B978-0-444-63849-6.00010-4

Abstract

Progressive multifocal leukoencephalopathy (PML) is a relatively common complication of HIV disease. In this chapter changes to the epidemiology are discussed along with an update in its pathogenesis and treatment. Immune reconstitution inflammatory syndrome is increasingly frequent in PML; accordingly management strategies and prognosis are detailed.

Keywords: HIV; IRIS; JCV; PML; maraviroc; mirtazepine.

Publication types

Review

MeSH terms

Animals
Brain / pathology
Brain / virology
HIV Infections / diagnosis*
HIV Infections / drug therapy*
HIV Infections / epidemiology
Humans
Immunosuppressive Agents / therapeutic use
Leukoencephalopathy, Progressive Multifocal / diagnosis*
Leukoencephalopathy, Progressive Multifocal / drug therapy
Leukoencephalopathy, Progressive Multifocal / epidemiology*

Substances

Immunosuppressive Agents